[Dopaminergic and noradrenergic therapy of cognitive impairment]
- PMID: 17069060
[Dopaminergic and noradrenergic therapy of cognitive impairment]
Abstract
The paper presents recent clinical data on usage of pronoran, a dopaminergic and noradrenergic medication, in the treatment of mild and moderate cognitive impairment in elderly. Efficacy of pronoran was shown in a number of placebo-controlled as well as open clinical trials including those carried out in Russia. Presented are also the results of the large-scale study PROMETEY which has been performed in Russia in 2004-2005. The study revealed that 70% of elderly neurological patients had cognitive impairment. Pronoran was included in the treatment of cognitive impairment in the frames of this study and showed a marked therapeutic effect in 82% cases.